Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters.

MLA

Valdera, Franklin A., et al. “Predictors and Benefits of Multiagent Chemotherapy for Pancreatic Adenocarcinoma: Timing Matters.” Journal of Surgical Oncology, vol. 129, no. 2, Feb. 2024, pp. 244–53. EBSCOhost, https://doi.org/10.1002/jso.27466.

APA

Valdera, F. A., O’Shea, A. E., Smolinsky, T. R., Carpenter, E. L., Adams, A. A., McCarthy, P. M., Tiwari, A., Chick, R. C., Kemp, B. P. M., Van Decar, S., Thomas, K. K., Bader, J. O., Peoples, G. E., Clifton, G. T., Stojadinovic, A., Nelson, D. W., & Vreeland, T. J. (2024). Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters. Journal of Surgical Oncology, 129(2), 244–253. https://doi.org/10.1002/jso.27466

Chicago

Valdera, Franklin A., Anne E. O’Shea, Todd R. Smolinsky, Elizabeth L. Carpenter, Alexandra A. Adams, Patrick M. McCarthy, Ankur Tiwari, et al. 2024. “Predictors and Benefits of Multiagent Chemotherapy for Pancreatic Adenocarcinoma: Timing Matters.” Journal of Surgical Oncology 129 (2): 244–53. doi:10.1002/jso.27466.